

Sir,

### **BTS/SIGN Guideline Query Doubling the dose of inhaled steroids**

We read with interest the correspondence on doubling the dose of inhaled corticosteroids during asthma exacerbations. As we were involved in writing and reviewing the section of the new BTS/SIGN guideline relating to this issue, we would like to make the following points.

When the effect of doubling the dose of inhaled corticosteroids has been investigated in tightly controlled clinical trials both in primary and secondary care settings, there has been no effect seen on exacerbations. The lack of any effect on exacerbations is almost certainly not due to inadequate trial design as the Foresi study, which investigated the effect of a five-fold increase in dose, was able to show a reduction in exacerbation frequency. On the other hand, self-management plans, which usually recommend a doubling of the dose of inhaled steroids at the time of an exacerbation, are clearly of benefit and are strongly endorsed in the new guidelines.

We think there are two possible explanations for this apparent paradox. As pointed out by some of your correspondents, self-management plans are a complex intervention and doubling the dose of inhaled steroids is only one component of this. It is quite possible that the effects seen when using a self-management plan for reducing exacerbations are due to other factors such as better compliance with regular treatment, earlier use of oral corticosteroids, or more appropriate behaviour during an exacerbation. An alternative explanation, and one that we favour, is that in the tightly controlled trials where compliance is good and usually of the order of 80-90%, patients are taking their regular inhaled steroids, and when they have an exacerbation the effect of doubling is not apparent. However, in the real-life studies of self-management plans, many patients as we know, stop taking their inhaled steroids completely. When they have an exacerbation of their asthma, they restart the inhaled steroids and the effect we see in the self-management plans is not really because of doubling, it is because of restarting inhaled steroids. Of course, one of the advantages of evidence-based guidelines is that they throw up these type of anomalies, which then generate research in order to try and arrive at an answer to the question.

Yours sincerely,

#### **Professor Neil Barnes**

Consultant Respiratory Physician, The London Chest Hospital, London

#### **Dr Bernard Higgins**

Consultant in Chest Conditions, Freeman Hospital, Newcastle

#### **Dr Graham Douglas**

Consultant in Respiratory Medicine, Aberdeen Royal Infirmary, Aberdeen

*Prim Care Respir J* 2003; **12**(3):99

Sir,

### **What constitutes an 'at risk' COPD patient?**

Last April I was dragged kicking and screaming onto the professional executive committee of our PCT. As a hospital practitioner for many years I was naturally made the respiratory lead GP. Two years ago the local hospital trust and PCG set up a 'telemedicine project' to monitor at risk COPD patients at home. The funding for this project was as per usual 'non recurring' so the new PCT is left with the job of sorting it out. We like the idea of targeting at risk COPD patients and wish by some early intervention to prevent expensive admissions to the DGH. The 'telemedicine' aspect of it with pulse oximeters at home etc is probably not cost effective. We hope that our respiratory nurse specialists will be able to contact these patients on a regular basis and nip in the bud any exacerbation.

But who are these at risk COPD patients? The telemedicine project was set up by simply asking the consultant chest physician for a list of suitable patients. We could also ask the GPs for a list as well but it's not very scientific. What do others do?

In Plymouth (Rupert Jones, personal communication), they concentrate their immediate care resources on COPD patients with the following:

- Those with previous admissions
- Social concerns
- Psychological concerns
- Long Term oxygen therapy
- Co-morbidity
- Nebulisers

David Bellamy (personal communication) says that we should consider those patients for close follow up who fall into the severe category i.e. <40% of predicted FEV<sub>1</sub>, those with respiratory or cardiac failure and those on long-term oxygen therapy (LTOT). My only problem with this is that I am sure that we can all think of patients cruising along with FEV<sub>1</sub>'s of 0.5 litre who pose no trouble to anyone?

The 'DOCTOR' magazine [3rd Feb 2003] pointed me to an article in *Thorax* (2003;**58**:100-5), 'Risk factors of readmission to hospital for a COPD exacerbation: a prospective study'. Its findings were:

- Activity > 60mins walk per day reduced hospital admissions by 50% even when corrected for severity of COPD
- Being under the care of the respiratory physician, on anticholinergics and oral steroids were all indicators of a higher re-admission rate
- The existence of a previous admission may play a role in 'confounding by indication'. The mere fact that there was a previous admission means that the patient was perceived to be a more severe case
- Influenza vaccination is associated with an increased risk of readmission (presumably because the less severe are less inclined to be vaccinated, thereby skewing the figures).
- Even passive smokers are at higher risk



# PRIMARY CARE RESPIRATORY JOURNAL

Journal of the General Practice Airways Group

Official Journal of the International Primary Care Respiratory Group

## Editorial

In this issue 76

*Paul Stephenson*

Rehabilitation for chronic lung disease: the challenge of implementation 77

*Mike Morgan*

The Cochrane Airways Group 2nd International Symposium 78

*Toby Lasserson*

It's good to talk...but do I really need to see you? The potential of telephone consultations for providing routine asthma care 79

*Hilary Pinnock*

IPCRG World Conference 2004 81

*Kathy Hope*

---

## Original Research

The impact of childhood asthma on daily life of the family - a qualitative study using recurrent thematic analysis 82

*Barbara Yawn*

Use of salmeterol/fluticasone combination (Seretide) in an asthma clinic: a pragmatic open study from primary care 86

*Christopher E Clark*

---

## Review

Early detection of chronic obstructive pulmonary disease (COPD): the role of spirometry as a diagnostic tool in primary care 90

*Onno van Schayck, Anthony D'Urzo, Giovanni Invernizzi, Miguel Román, Björn Stållberg, Christopher Urbina*

---

## Stop Think

Stop Think: dyspnoea and an abnormal chest x-ray 94

*Praveen Bhatia, Ravish Katira, S Karthik, E Li-Kam-Wa*

---

## Regular Features

GPIAG Aberdeen research team news 95

Members, colleagues and international news 97

Letters to the Editor 99

Authors notes 101